Company Profile
BioDlink International Company Limited, an investment holding company provides the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and globally.
The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer. Its portfolio also includes advanced, metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma multiforme, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and cervical cancer
Tazian, a temozolomide capsule for the treatment of glioblastoma and anaplastic astrocytoma. Additionally, it develops TAB014 a bevacizumab ophthalmic drug for the treatment of wet age-related macular degeneration (wAMD) contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business.
Its portfolio also includes license-out of self-developed biological drugs, and business development, investing, and marketing promotion activities. Incorporated in 2009 and headquartered in Suzhou, China, BioDlink International was formerly known as TOT BIOPHARM International Company Limited before rebranding in July 2025. BioDlink International Company Limited operates as a subsidiary of WuXi XDC Cayman Inc.